North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme
Jann N. Sarkaria(Mayo Clinic), Jan C. Buckner(McGill University), Kurt A. Jaeckle(Jacksonville College), Joon H. Uhm(Mayo Clinic), Paul D. Brown(The University of Texas MD Anderson Cancer Center), Caterina Giannini(Mayo Clinic), Steven McGraw(Montana Cancer Consortium), Wenting Wu(Wenzhou Institute of Industrial Science), Patrick J. Peller(Mayo Clinic), Evanthia Galanis(The University of Texas at San Antonio Health Science Center)
International Journal of Radiation Oncology*Biology*Physics
September 24, 2010
Cited by 89
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k